Respirerx Pharmaceuticals Stock Net Income
| RSPI Stock | USD 0 0.00 0.00% |
Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of RespireRx Pharmaceuticals, as well as the relationship between them.
RespireRx Pharmaceuticals' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing RespireRx Pharmaceuticals' valuation are provided below:RespireRx Pharmaceuticals does not presently have any trending fundamental ratios for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. RespireRx |
RespireRx Pharmaceuticals 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to RespireRx Pharmaceuticals' pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of RespireRx Pharmaceuticals.
| 11/15/2025 |
| 02/13/2026 |
If you would invest 0.00 in RespireRx Pharmaceuticals on November 15, 2025 and sell it all today you would earn a total of 0.00 from holding RespireRx Pharmaceuticals or generate 0.0% return on investment in RespireRx Pharmaceuticals over 90 days. RespireRx Pharmaceuticals is related to or competes with Comjoyful International. RespireRx Pharmaceuticals Inc. engages in the discovery, development, and commercialization of pharmaceuticals for the t... More
RespireRx Pharmaceuticals Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure RespireRx Pharmaceuticals' pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess RespireRx Pharmaceuticals upside and downside potential and time the market with a certain degree of confidence.
RespireRx Pharmaceuticals Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for RespireRx Pharmaceuticals' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as RespireRx Pharmaceuticals' standard deviation. In reality, there are many statistical measures that can use RespireRx Pharmaceuticals historical prices to predict the future RespireRx Pharmaceuticals' volatility.RespireRx Pharmaceuticals Backtested Returns
We have found three technical indicators for RespireRx Pharmaceuticals, which you can use to evaluate the volatility of the company. The company holds a Beta of 0.0, which implies not very significant fluctuations relative to the market. the returns on MARKET and RespireRx Pharmaceuticals are completely uncorrelated.
Auto-correlation | 0.00 |
No correlation between past and present
RespireRx Pharmaceuticals has no correlation between past and present. Overlapping area represents the amount of predictability between RespireRx Pharmaceuticals time series from 15th of November 2025 to 30th of December 2025 and 30th of December 2025 to 13th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of RespireRx Pharmaceuticals price movement. The serial correlation of 0.0 indicates that just 0.0% of current RespireRx Pharmaceuticals price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.0 | |
| Spearman Rank Test | 1.0 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, RespireRx Pharmaceuticals reported net income of (3.14 Million). This is 100.92% lower than that of the Pharmaceuticals sector and 104.49% lower than that of the Health Care industry. The net income for all United States stocks is 100.55% higher than that of the company.
RespireRx Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses RespireRx Pharmaceuticals' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of RespireRx Pharmaceuticals could also be used in its relative valuation, which is a method of valuing RespireRx Pharmaceuticals by comparing valuation metrics of similar companies.RespireRx Pharmaceuticals is currently under evaluation in net income category among its peers.
RespireRx Fundamentals
| Return On Asset | -8.34 | |||
| Current Valuation | 3.18 M | |||
| Shares Outstanding | 119.59 M | |||
| Shares Owned By Insiders | 20.63 % | |||
| Number Of Shares Shorted | 126 | |||
| Price To Earning | (0.25) X | |||
| Price To Sales | 1,051 X | |||
| EBITDA | (2.42 M) | |||
| Net Income | (3.14 M) | |||
| Cash And Equivalents | 21 | |||
| Total Debt | 2.42 M | |||
| Current Ratio | 0.01 X | |||
| Book Value Per Share | (0.1) X | |||
| Cash Flow From Operations | (956.17 K) | |||
| Short Ratio | 1.47 X | |||
| Earnings Per Share | (0.04) X | |||
| Target Price | 0.3 | |||
| Beta | 0.24 | |||
| Market Capitalization | 837.16 K | |||
| Total Asset | 208.74 K | |||
| Retained Earnings | (156.09 M) | |||
| Working Capital | (4.89 M) | |||
| Current Asset | 157 K | |||
| Current Liabilities | 5.05 M | |||
| Net Asset | 208.74 K |
About RespireRx Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze RespireRx Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of RespireRx Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of RespireRx Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Other Information on Investing in RespireRx Pink Sheet
RespireRx Pharmaceuticals financial ratios help investors to determine whether RespireRx Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in RespireRx with respect to the benefits of owning RespireRx Pharmaceuticals security.